Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EHA 25 European Perspectives Webinar: CLL

Published on: 22.06.2020, 41 min.

In this webinar, Prof. Dr. Arnon Kater, Prof. Dr. Clemens Wendtner and Prof. Dr. Davide Rossi discuss three practice changing studies on CLL.

Study 1 summarised by Prof. Dr. Arnon Kater

EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL
PHASE 3B TRIAL (VENICE I)

Study 2 summarised by Prof. Dr. Clemens Wendtner

S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL

Study 3 summarised by Prof. Dr. Davide Rossi

S 158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT

 

The webinar was independently produced and paid for by the MEDtalks Group of Companies.

  • Partner


    This program has been produced by our partner: